CEO John Rim eyes further US capacity growth after GSK Rockville acquisition

SAN FRANCISCO — Samsung Biologics CEO John Rim reiterated the Korean contract development and manufacturing organization, or CDMO, leader's strengths in production capacity, diversifying portfolio and global expansion to maintain growth.

"We've consistently said we will do three things: increase our geographic coverage to be close to our customer, increase our portfolio to provide more one-time service to customers in terms of their needs and then continue to expand capac

📰

Continue Reading on The Korea Herald

This preview shows approximately 15% of the article. Read the full story on the publisher's website to support quality journalism.

Read Full Article →